Most early stage stem cell investors have lost their shirts, admits a market commentator as it puts forward the case for investment in a handful or current biotech companies that might be worth a punt.
Microcap Speculators, which provides reports, company profiles and other investor relations materials, has published a commentary on these companies and the wider area of research, entitled The Big Deal About Stem Cell Therapies and Regenerative Medicine.
"The dot-com like era of regenerative medicine is over. Investors will need to look at companies solving issues with stem cells or those taking a completely new approach"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze